Emergent Biosolutions (EBS) Expected to Announce Earnings on Wednesday

Emergent Biosolutions (NYSE:EBS) will likely be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.0850) per share and revenue of $177.50 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 5:00 PM ET.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.46. The firm had revenue of $156.10 million during the quarter, compared to analyst estimates of $145.00 million. Emergent Biosolutions had a positive return on equity of 10.76% and a negative net margin of 1.27%.

Emergent Biosolutions Trading Down 0.2%

EBS opened at $7.21 on Monday. The company has a quick ratio of 2.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.10. The stock’s fifty day moving average is $8.06 and its two-hundred day moving average is $8.93. The company has a market capitalization of $371.78 million, a P/E ratio of -25.73 and a beta of 2.35. Emergent Biosolutions has a 52 week low of $5.61 and a 52 week high of $14.06.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on EBS shares. Weiss Ratings downgraded Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. UBS Group restated a “buy” rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Finally, Benchmark reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.00.

Insiders Place Their Bets

In related news, SVP Paul Anthony Williams sold 3,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total transaction of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares of the company’s stock, valued at $1,336,423.20. This represents a 1.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Emergent Biosolutions

A number of large investors have recently modified their holdings of EBS. CANADA LIFE ASSURANCE Co acquired a new position in shares of Emergent Biosolutions during the fourth quarter valued at about $45,000. Legal & General Group Plc acquired a new stake in Emergent Biosolutions in the 2nd quarter worth approximately $31,000. Raymond James Financial Inc. purchased a new stake in Emergent Biosolutions during the 2nd quarter worth approximately $53,000. Kemnay Advisory Services Inc. purchased a new stake in Emergent Biosolutions during the 4th quarter worth approximately $107,000. Finally, Abel Hall LLC acquired a new position in Emergent Biosolutions during the 4th quarter valued at approximately $129,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.